Shares of the e-signature provider DocuSign (DOCU) are down about 8.5% in the last three months. The weakness in DocuSign is due to the sequential slowdown in growth rate, and tough year-over-year comparisons.
Interestingly, DocuSign witnessed a stellar demand for its products amid the pandemic. Thanks to favorable industry trends, DocuSign stock surged nearly 200% in 2020.
However, the economic reopening, and normalization in demand trends weighed on DocuSign stock. DocuSign’s top-line growth slowed to 50% in Q2 from 58% in Q1. Further, its billings growth rate moderated to 47% from 54% in Q1.
As for Q3, DocuSign expects its revenue to increase by 37% to 39% year-over-year, indicating a further deceleration in growth rate. Billings are projected to increase by 33% to 36%, a much slower pace than Q2.
Owing to its moderating growth rate, investors maintain a Very Negative outlook on DocuSign stock. TipRanks’ Stock Investors tool shows that 6.8% of investors who hold portfolios on TipRanks have cut their exposure in the last 30 days.
While DocuSign’s Q2 revenue growth rate moderated, it remained higher than the pre-pandemic levels despite being up against tougher comparisons.
In response to DocuSign’s moderating growth, Scott Berg of Needham said that the deceleration was “at a much slower rate” than the Street’s expectations. Berg expects DocuSign to exceed sales expectations.
Berg has a Buy rating on DocuSign stock, and a price target of $340 (21.5% upside potential).
Along with Berg, the majority of analysts maintain a favorable view on DocuSign stock. It sports a rating consensus of Strong Buy, based on 15 Buys and one Hold.
The average DocuSign price target of $336.36 implies 20.1% upside potential to current levels.
Disclosure: On the date of publication, Amit Singh had no position in any of the companies discussed in this article.
Disclaimer: The information contained in this article represents the views and opinion of the writer only, and not the views or opinion of TipRanks or its affiliates, and should be considered for informational purposes only. TipRanks makes no warranties about the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or solicitation to purchase or sell securities. Nothing in the article constitutes legal, professional, investment and/or financial advice and/or takes into account the specific needs and/or requirements of an individual, nor does any information in the article constitute a comprehensive or complete statement of the matters or subject discussed therein. TipRanks and its affiliates disclaim all liability or responsibility with respect to the content of the article, and any action taken upon the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not indicative of future results, prices or performance.